Eli Lilly and Company
Pharmaceutical & Health Products · Lobbying Client
B
Influence Score
68/100
High Influence
$22.9M
Total Lobby Spend
6
Policy Issues
9
Lobbyists
4
Revolving Door
Eli Lilly and Company reported $22.9 million in federal lobbying expenditures as disclosed in Senate LDA filings. The organization's lobbying activity spans 6 policy areas, with primary focus on Health Issues, Pharmacy, Medical/Disease Research. This data is drawn from quarterly disclosure reports filed with the Secretary of the Senate under the Lobbying Disclosure Act of 1995.
Annual Lobbying Spend
Policy Issues
Government Entities Contacted
Dept of Interior
White House
Small Business Administration
Dept of Housing & Urban Development
Dept of Treasury
Dept of Labor
US Senate
Recent Filings
| Period | Registrant | Issues | Lobbyists | Amount |
|---|---|---|---|---|
| 2020 Jan-Mar | Squire Patton Boggs LLP | PHA | 3 | $1.1M |
| 2020 Apr-Jun | Holland & Knight LLP | TAXCPT | 2 | $1.2M |
| 2020 Jul-Sep | Brownstein Hyatt LLP | PHAHCRTAX+2 | 2 | $1.1M |
| 2020 Oct-Dec | Akin Gump LLP | PHA | 2 | $1.0M |
| 2021 Jan-Mar | BGR Group LLP | MEDCPTTAX+2 | 3 | $648K |
| 2021 Apr-Jun | Squire Patton Boggs LLP | TAXPHAMED | 2 | $954K |
| 2021 Jul-Sep | BGR Group LLP | GOVPHA | 2 | $869K |
| 2021 Oct-Dec | Squire Patton Boggs LLP | GOVCPTMED+2 | 1 | $1.0M |